A Phase 3 interventional study of IPX066 in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 8 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-11-07.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 8th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 9th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2011.
This study's enrollment of 43 is close to the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study had three distinct parts and is described as follows:
Part 1:
Part 2:
Part 3:
Part 1: This study was a multicenter, open-label study. Subjects were to be converted from their previous CD-LD treatment to IPX066 over a 6-week period. Up to 40 subjects were to be enrolled in the study. Enrollment was defined as subjects who received study drug in Part 1 - Visit 1. Subjects were to be entered into one of two cohorts.
Approximately 24 subjects were to enroll in Cohort 1 (non-OPDM subjects) and up to 16 subjects at selected sites were to enroll in Cohort 2 (OPDM subjects). For the subjects enrolled in Cohort 2, along with the OPDM measurements, PK blood samples were also to be collected.
Part 2: Following the successful completion of Part 1 of the study, eligible subjects could participate in Part 2, a 6-month open-label extension study.
Part 3: Following the successful completion of Part 2 of the study, eligible subjects could participate in Part 3, an additional 6-month open-label extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently being treated with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
Drug: IPX066
Subjects were converted from their current treatment to IPX066 over a 6-week period. Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules
Also known as: ER CD-LD
Patient Global Impression (PGI)
At Part 1 Week 6, Part 2 Month 3 and Month 6 or at Early Termination, the subjects rated the change in their condition with IPX066 treatment from their condition prior to Part 1 Visit 1(Baseline) using Patient Global Impression (PGI) 7-point scale. 1=very much worse and 7=very much improved.
Time frame: 6 months
Clinical Global Impression (CGI)
Clinician-reported satisfaction outcome of IPX066 using Clinical Global Impression (PGI) 7-point scale. At Part 1 Week 6; Part 2 Month 3, and Month 6 or at Early Termination, the Investigator rated how much a subject's overall condition had changed since Part 1 Visit 1 (Baseline) using 7-point scale. 1=very much worse and 7=very much improved.
Time frame: 6 months
Parkinson's Disease Questionnaire-8 (PDQ-8)
Change from Baseline in Parkinson's disease Questionnaire-8 (PDQ-8) at End of Study or early discontinuation. The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms, each item ranging from 0 to 4, and the responses consist of 0=Never, 1=Occasionally, 2=Sometimes, 3=Often, and 4=Always or cannot do at all, total score ranging from 0 (never have problems/issues) to 32 (always have problems or cannot do at all).
Time frame: 6 months
Date first subject enrolled: August 19, 2011 Date last subject completed: March 20, 2013
| Milestone | IPX066 |
|---|---|
| Started | 43 |
| Completed | 33 |
| Not completed | 10 |
| Milestone | IPX066 |
|---|---|
| Started | 32 |
| Completed | 25 |
| Not completed | 7 |
| Milestone | IPX066 |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
At Part 1 Week 6, Part 2 Month 3 and Month 6 or at Early Termination, the subjects rated the change in their condition with IPX066 treatment from their condition prior to Part 1 Visit 1(Baseline) using Patient Global Impression (PGI) 7-point scale. 1=very much worse and 7=very much improved.
| units on a scale | Part 1: Conversion | Part 2: Open-Label Extension (Month 3) | Part 2: Open-Label Extension (Month 6) | Part 1 or 2 Early Termination |
|---|---|---|---|---|
| Patient Global Impression (PGI) | 5.2 ± 1.35 | 5.4 ± 1.30 | 5.3 ± 1.49 | 2.8 ± 1.21 |
Clinician-reported satisfaction outcome of IPX066 using Clinical Global Impression (PGI) 7-point scale. At Part 1 Week 6; Part 2 Month 3, and Month 6 or at Early Termination, the Investigator rated how much a subject's overall condition had changed since Part 1 Visit 1 (Baseline) using 7-point scale. 1=very much worse and 7=very much improved.
| units on a scale | Part 1: Conversion | Part 2: Open-Label Extension (Month 3) | Part 2: Open-Label Extension (Month 6) | Part 1 or 2 Early Termination |
|---|---|---|---|---|
| Clinical Global Impression (CGI) | 5.5 ± 1.15 | 5.7 ± 1.08 | 5.6 ± 1.39 | 3.7 ± 0.80 |
Change from Baseline in Parkinson's disease Questionnaire-8 (PDQ-8) at End of Study or early discontinuation. The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms, each item ranging from 0 to 4, and the responses consist of 0=Never, 1=Occasionally, 2=Sometimes, 3=Often, and 4=Always or cannot do at all, total score ranging from 0 (never have problems/issues) to 32 (always have problems or cannot do at all).
| units on a scale | Part 1: Conversion (Baseline) | Part 1: Conversion (Week 6) | Part 2: Open-Label Extension (Month 3) | Part 2: Open-Label Extension (Month 6) | Part 1 or 2 Early Termination |
|---|---|---|---|---|---|
| Parkinson's Disease Questionnaire-8 (PDQ-8) | 9.6 ± 5.49 | 8.1 ± 4.62 | 8.5 ± 4.79 | 9.0 ± 5.91 | 11.8 ± 6.62 |
Collected over 58 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Conversion | — | 1/43 (2.3%) | 18/43 (41.9%) |
| Part 2: Open-Label Extension 1 | — | 5/32 (15.6%) | 17/32 (53.1%) |
| Part 3: Open-Label Extension 2 | — | 3/12 (25%) | 9/12 (75%) |
| Overall | — | 9/43 (20.9%) | 35/43 (81.4%) |
| Event | Part 1: Conversion | Part 2: Open-Label Extension 1 | Part 3: Open-Label Extension 2 | Overall |
|---|---|---|---|---|
| Orthostatic HypotensionVascular disorders | 0/43 | 0/32 | 2/12 | 2/43 |
| Cerebrovascular accidentNervous system disorders | 0/43 | 1/32 | 1/12 | 2/43 |
| Atrial FibrillationCardiac disorders | 1/43 | 1/32 | 0/12 | 1/43 |
| Parkinson's diseaseNervous system disorders | 0/43 | 1/32 | 0/12 | 1/43 |
| AnxietyPsychiatric disorders | 0/43 | 1/32 | 0/12 | 1/43 |
| SepsisInfections and infestations | 0/43 | 1/32 | 0/12 | 1/43 |
| Back PainMusculoskeletal and connective tissue disorders | 0/43 | 1/32 | 0/12 | 1/43 |
| Event | Part 1: Conversion | Part 2: Open-Label Extension 1 | Part 3: Open-Label Extension 2 | Overall |
|---|---|---|---|---|
| Upper Respiratory InfectionInfections and infestations | 3/43 | 5/32 | 0/12 | 8/43 |
| FallInjury, poisoning and procedural complications | 3/43 | 2/32 | 2/12 | 5/43 |
| Orthostatic HypotensionVascular disorders | 0/43 | 2/32 | 2/12 | 3/43 |
| NauseaGastrointestinal disorders | 5/43 | 2/32 | 0/12 | 7/43 |
| AnxietyPsychiatric disorders | 2/43 | 2/32 | 1/12 | 5/43 |
| DyskinesiaNervous system disorders | 3/43 | 1/32 | 0/12 | 4/43 |
| Drug ToxicityInjury, poisoning and procedural complications | 0/43 | 0/32 | 1/12 | 1/43 |
| DepressionPsychiatric disorders | 0/43 | 0/32 | 1/12 | 1/43 |
| Renal Failure AcuteRenal and urinary disorders | 1/43 | 1/32 | 1/12 | 2/43 |
| Dermatitis ContactSkin and subcutaneous tissue disorders | 0/43 | 0/32 | 1/12 | 1/43 |
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 20 |
| >=65 years | 23 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 66.4 ± 10.49 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 23 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 43 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 42 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | All Study Participants |
|---|---|
| United States | 43 |
Plan to share: No
The record gives a start of Aug 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 4 years 1 month after primary completion. A results delay was requested in Sep 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.